SEELQ (Seelos Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


SEELQ Seelos Therapeutics Inc SEELQ
16 GF Score
Price $0.00
View Full Analysis

What is Seelos Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Seelos Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

SEELQ vs NTBLQ, EFTR, MTEM: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Seelos Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seelos Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


SEELQ
16GF Score
Seelos Therapeutics Inc SEELQ
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seelos Therapeutics Business Description

Address 300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
16GF Score

Get the complete analysis for SEELQ

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price